BACKGROUND: It remains uncertain why immunocompetent patients with bacterial community-acquired pneumonia (CAP) die, in spite of adequate antibiotics. METHODS: This is a secondary analysis of the CAPUCI database which was a prospective observational multicentre study. Two hundred and twelve immunocompetent patients admitted to 33 Spanish ICUs for CAP were analyzed. Comparisons were made for lifestyle risk factors, comorbidities and severity of illness. ICU mortality was the principal outcome variable. RESULTS: Bacteremic CAP (43.3 vs. 21.1%) and empyema (11.5 vs. 2.2%) were more frequent (P < 0.05) in patients with Streptococcus pneumoniae CAP. Higher rates of adequate empiric therapy (95.8 vs. 75.5%, P < 0.05) were observed in patients with S. pneumoniae CAP. Patients with non-pneumococcal CAP experienced more shock (66.7 vs. 50.8%, P < 0.05), and need for mechanical ventilation (83.3 vs. 61.5%, P < 0.05). ICU mortality was 20.7 and 28% [OR 1.49(0.74-2.98)] among immunocompetent patients with S. pneumoniae (n = 122) and non-pneumococci (n = 90), in spite of initial adequate antibiotic. Multivariable regression analysis in these 184 immunocompetent patients with adequate empirical antibiotic treatment identified the following variables as independently associated with mortality: shock (HR 13.03); acute renal failure (HR 4.79), and APACHE II score higher than 24 (HR 2.22). CONCLUSIONS: Mortality remains unacceptably high in immunocompetent patients admitted to the ICU with bacterial pneumonia, despite adequate initial antibiotics and comorbidities management. Patients with shock, acute renal failure and APACHE II score higher than 24 should be considered for inclusion in trials of adjunctive therapy in order to improve CAP survival.
BACKGROUND: It remains uncertain why immunocompetent patients with bacterial community-acquired pneumonia (CAP) die, in spite of adequate antibiotics. METHODS: This is a secondary analysis of the CAPUCI database which was a prospective observational multicentre study. Two hundred and twelve immunocompetent patients admitted to 33 Spanish ICUs for CAP were analyzed. Comparisons were made for lifestyle risk factors, comorbidities and severity of illness. ICU mortality was the principal outcome variable. RESULTS: Bacteremic CAP (43.3 vs. 21.1%) and empyema (11.5 vs. 2.2%) were more frequent (P < 0.05) in patients with Streptococcus pneumoniae CAP. Higher rates of adequate empiric therapy (95.8 vs. 75.5%, P < 0.05) were observed in patients with S. pneumoniae CAP. Patients with non-pneumococcal CAP experienced more shock (66.7 vs. 50.8%, P < 0.05), and need for mechanical ventilation (83.3 vs. 61.5%, P < 0.05). ICU mortality was 20.7 and 28% [OR 1.49(0.74-2.98)] among immunocompetent patients with S. pneumoniae (n = 122) and non-pneumococci (n = 90), in spite of initial adequate antibiotic. Multivariable regression analysis in these 184 immunocompetent patients with adequate empirical antibiotic treatment identified the following variables as independently associated with mortality: shock (HR 13.03); acute renal failure (HR 4.79), and APACHE II score higher than 24 (HR 2.22). CONCLUSIONS: Mortality remains unacceptably high in immunocompetent patients admitted to the ICU with bacterial pneumonia, despite adequate initial antibiotics and comorbidities management. Patients with shock, acute renal failure and APACHE II score higher than 24 should be considered for inclusion in trials of adjunctive therapy in order to improve CAP survival.
Authors: Lala M Dunbar; Richard G Wunderink; Michael P Habib; Leon G Smith; Alan M Tennenberg; Mohammed M Khashab; Barbara A Wiesinger; Jim X Xiang; Neringa Zadeikis; James B Kahn Journal: Clin Infect Dis Date: 2003-08-28 Impact factor: 9.079
Authors: Grant W Waterer; Steven C Buckingham; Lori A Kessler; Michael W Quasney; Richard G Wunderink Journal: Chest Date: 2003-08 Impact factor: 9.410
Authors: Jeffrey A Claridge; Priscilla Pang; William H Leukhardt; Joseph F Golob; Jeffrey W Carter; Adam M Fadlalla Journal: Surg Infect (Larchmt) Date: 2010-04 Impact factor: 2.150
Authors: Massimo Antonelli; Elie Azoulay; Marc Bonten; Jean Chastre; Giuseppe Citerio; Giorgio Conti; Daniel De Backer; François Lemaire; Herwig Gerlach; Goran Hedenstierna; Michael Joannidis; Duncan Macrae; Jordi Mancebo; Salvatore M Maggiore; Alexandre Mebazaa; Jean-Charles Preiser; Jerôme Pugin; Jan Wernerman; Haibo Zhang Journal: Intensive Care Med Date: 2010-01-08 Impact factor: 17.440
Authors: M Isabel García-Laorden; Felipe Rodríguez de Castro; Jordi Solé-Violán; Olga Rajas; José Blanquer; Luis Borderías; Javier Aspa; M Luisa Briones; Pedro Saavedra; J Alberto Marcos-Ramos; Nereida González-Quevedo; Ithaisa Sologuren; Estefanía Herrera-Ramos; José M Ferrer; Jordi Rello; Carlos Rodríguez-Gallego Journal: Crit Care Date: 2011-02-10 Impact factor: 9.097
Authors: Sarah E Siegelaar; Maartje Hickmann; Joost B L Hoekstra; Frits Holleman; J Hans DeVries Journal: Crit Care Date: 2011-09-13 Impact factor: 9.097
Authors: Jos Van Oers; Johannes Krabbe; Evelien Kemna; Yvette Kluiters; Piet Vos; Dylan De Lange; Armand Girbes; Albertus Beishuizen Journal: Cureus Date: 2021-05-28